Coherus Oncology
CHRS
77 hedge funds and large institutions have $384M invested in Coherus Oncology in 2015 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 16 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 23
19% more capital invested
Capital invested by funds: $322M → $384M (+$61.5M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
1% less funds holding
Funds holding: 78 → 77 (-1)
55% less call options, than puts
Call options by funds: $122K | Put options by funds: $272K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.4M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$12.1M |
| 3 |
JP Morgan Chase
New York
|
+$7.24M |
| 4 |
TA
Teachers Advisors
New York
|
+$2.38M |
| 5 |
IHM
Iguana Healthcare Management
New York
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tourbillon Capital Partners
New York
|
-$15.7M |
| 2 |
VM
VHCP Management
New York
|
-$6.67M |
| 3 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$4.54M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.25M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$3.21M |
CHRS Hedge Fund Activity: Q4 2015 in Review
77 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2015, worth a combined $384M — up 19% from $322M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CHRS and 15 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 30 added.
The largest buyer was Fidelity Investments, adding an estimated $34.4M. The largest seller was Tourbillon Capital Partners, exiting entirely with an estimated $15.7M sold.
- 77 institutional investors held Coherus Oncology (CHRS) as of Q4 2015, down from 78 in Q3 2015.
- Funds reported $384M of Coherus Oncology stock for Q4 2015, up 19% quarter-over-quarter.
- 15 funds opened new Coherus Oncology positions in Q4 2015 and 16 closed out, a net change of -1 holder.
- The largest Coherus Oncology buyer in Q4 2015 was Fidelity Investments, an estimated $34.4M added.
- The largest Coherus Oncology seller in Q4 2015 was Tourbillon Capital Partners, an estimated $15.7M sold.
Based on aggregated 13F filings for Q4 2015.